ABC | Volume 110, Nº3, Março 2018

Artigo de Revisão Ker et al Implicações práticas da pesquisa de viabilidade miocárdica Arq Bras Cardiol. 2018; 110(3):278-288 25. Marzullo P, Parodi O, Reisenhofer B, Sambuceti G, Picano E, Distante A, et al. Value of rest – thallium-201/technetium-99 sestamibi and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol. 1993;71(2):166-72. 26. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med. 2007;48(7):1135-46. 27. Giogetti A, Marzullo P, Sambuceti G, Di Quirico S, Kusch A, Landi P, et al; Baseline/postnitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging. J Nucl Cardiol. 2004;11(12):142-51. 28. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375-410. 29. SciagraR,PellegriM,PupiA,BologneseL,BisiG,CarnovaleV,etal.Prognostic implicationsofTc-99msestamibiviability imagingandsubsequenttherapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J AmColl Cardiol. 2000;36(3):739-45. 30. Tillisch J, Brunken R, Marshall R, Schwaiger M, MandelkernM, Phelps M, et al. Reversibility of cardial wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884-8. 31. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med. 1994;35(4):707-15. 32. Marshall RC, Tillisch JH, Phelps ME, Huang SC, Carson R, Henze E, et al. Identification and differentiation of restingmyocardial ischemia inmanwith positron computed tomography, 18F-labeled fluorodeoxyglucose, andN-13 ammonia. Circulation. 1983;67(4):766-78. 33. Goldstein R, Mullani N, Wong W, Hartz RK, Hicks CH, Fuentes F, et al. Positron imaging of myocardial infarction with rubidium-82. J Nucl Med. 1986;27(12):1824-9. 34. Gould K, Goldstein R, Mullani N, Kirkeeide RL, Wong WH, Tewson TJ, et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82.; J Am Cardiol. 1986;7(4):775-89. 35. Goldstein RA. Rubidium-82 kinetics after coronary occlusion: temporal relation net myocardial accumulation and viability in open-chested dogs. J Nucl Med. 1986;27(9):1456-61. 36. Stankewicz MA, Mansour CS, Eisner RL, Churchwell KB, Williams BR, Sigman SR, et al. Myocardial viability assessment by PET: 82Rb defect washout does not predict the results of metabolic–perfusion mismatch. J Nucl Med. 2005;46(10):1602-9. 37. Sampson UK, Dorbala S, Limaye A, Di Carli MF. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/computed tomography in the detection of coronary artery disease. J Am Coll Cardiol. 2007;49(10):1052-8. 38. Knesaurek K, Machac J, Krynyckyi BR, Almeida OD. Comparison of 2- dimensional and 3-dimensional 82Rb myocardial perfusion PET imaging. J Nucl Med. 2003;44(8):1350-6. 39. Krivokapich J, Smith GT, Huang SC, Hoffman EJ, Ratib O, Phelps ME, et al. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers: quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation. 1989;80(5):1328-37. 40. Van den Hoff J, Burchert W, Borner AR, Fricke H, Kuhnel G, Meyer GJ, et al. [1-(11)C] acetate as a quantitative perfusion tracer inmyocardial PET. J Nucl Med. 2001;42(8):1174-82. 41. PartingtonSL,KwongRY,DorbalaS.Multimodality imaging intheassessment of myocardial viability. Heart Fail Rev. 2011;16(4):381-95. 42. AchenbachS.CardiacCT:stateoftheart forthedetectionofcoronaryarterial stenosis. J Cardiovasc Comput Tomogr. 2007;1(1):3-20. 43. Brodoefel H, Klumpp B, Reimann A, Fenchel M, Heuschmid M, Miller S, et al. Sixty-four-MSCT in the characterization of porcine acute and subacute myocardialinfarction:determinationoftransmuralityincomparisontomagnetic resonance imaging and histopathology. Eur J Radiol. 2007;62(2):235-46. 44. Romero J, Xue X, Gonzalez W, Garcia MJ. CMR imaging assessing viability in patients with chronic ventricular dysfunction due to coronary artery disease: a meta-analysisofprospectivetrials.JACCCardiovascImaging.2012;5(5):494-508. 45. Hammermeister KE, DeRouen TA, DodgeHT. Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation. 1979;59(3):421-30. 46. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445-53. 47. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascularmagnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110(12):1535-41. 48. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1):215-23. 49. GerberBL,RousseauMF,AhnSA, lePolaindeWarouxJB,PouleurAC,PhlipsT, et al. Prognostic value of myocardial viability by delayed-enhancedmagnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J AmColl Cardiol. 2012;59(9):825-35 50. Sara L, Szarf G, Tachibana A, Shiozaki AA, Villa AV, de Oliveira AC, et al; Sociedade Brasileira de Cardiologia, Colegio Brasileiro de Radiologia. [II Guidelines on Cardiovascular Magnetic Resonance and Computed Tomography of the Brazilian Society of Cardiology and the Brazilian College of Radiology]. Arq Bras Cardiol. 2014;103(6 Suppl 3):1-86. 51. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation. 2002;105(2):162-7. 52. Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ. 68Ga- NODAGA-RGD is a suitable substitute for 18FGalacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol. 2012;39(6):777-84. 53. Higuchi T, Nekolla SG, Jankaukas A,Weber AW, HuismanMC, Reder S, et al. Characterizationofnormaland infarctedratmyocardiumusingacombination of small-animal PET and clinical MRI. J Nucl Med. 2007;48(2):288-94. 54. Panza JA, Dilsizian V, Laurienzo JM, Curiel RV, Katsiyiannis PT. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary arterydiseaseand leftventriculardysfunction.Circulation.1995;91(4):990-8. 55. SadeghianH,Majd-Ardakani J,Lotfi-TokaldanyM, JahangiriC,FathollahiMS. Comparison between dobutamine stress echocardiography andmyocardial perfusion scan to detect viablemyocardium in patients with coronary artery disease and low ejection fraction. Hellenic J Cardiol. 2009;50(1):45-51. 56. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart. 1998;79(3):281-8. 57. Barrington SF, Chambers J, Hallett WA, O’DohertyMJ, Roxburgh JC, Nunan TO. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging. 2004;31(3):355-61. 58. Rahimtoola SH. Concept and evaluation of hibernatingmyocardium. Annu Rev Med. 1999;50:75-86. 287